274 related articles for article (PubMed ID: 29673889)
1. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
3. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
5. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
6. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
7. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
Frankenburg S; Glick D; Klaus S; Barenholz Y
Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
[TBL] [Abstract][Full Text] [Related]
8. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
[TBL] [Abstract][Full Text] [Related]
9. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
[TBL] [Abstract][Full Text] [Related]
10. Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.
Wijnant GJ; Van Bocxlaer K; Fortes Francisco A; Yardley V; Harris A; Alavijeh M; Murdan S; Croft SL
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082295
[TBL] [Abstract][Full Text] [Related]
11. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.
Daftarian PM; Stone GW; Kovalski L; Kumar M; Vosoughi A; Urbieta M; Blackwelder P; Dikici E; Serafini P; Duffort S; Boodoo R; Rodríguez-Cortés A; Lemmon V; Deo S; Alberola J; Perez VL; Daunert S; Ager AL
J Infect Dis; 2013 Dec; 208(11):1914-22. PubMed ID: 23901083
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
14. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
15. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.
Asad M; Bhattacharya P; Banerjee A; Ali N
BMC Infect Dis; 2015 Apr; 15():188. PubMed ID: 25884796
[TBL] [Abstract][Full Text] [Related]
17. Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.
Corware K; Harris D; Teo I; Rogers M; Naresh K; Müller I; Shaunak S
Biomaterials; 2011 Nov; 32(31):8029-39. PubMed ID: 21807409
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.
Iman M; Huang Z; Szoka FC; Jaafari MR
Int J Pharm; 2011 Apr; 408(1-2):163-72. PubMed ID: 21277963
[TBL] [Abstract][Full Text] [Related]
20. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.
Yardley V; Croft SL
Antimicrob Agents Chemother; 1997 Apr; 41(4):752-6. PubMed ID: 9087483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
